外周血miR-338-5p、miR-140-5p在HBV相关肝细胞癌患者中表达水平及临床意义  

Expression levels and clinical significance of miR-338-5p and miR-140-5p in peripheral blood of patients with HBV-related hepatocellular carcinoma

作　　者：侯悦[1] 张金仿[1] 马开慧[1] 郑艳 HOU Yue;ZHANG Jinfang;MA Kaihui;ZHENG Yan(Clinical Laboratory Center of Beijing Friendship Hospital Affiliated to Capital Medical University,100050,China)

机构地区：[1]首都医科大学附属北京友谊医院临床检验中心,100050

出　　处：《传染病信息》2023年第4期305-310,共6页Infectious Disease Information

摘　　要：目的 探讨外周血血清中微小RNA(microRNA, miR)-338-5p、miR-140-5p在HBV相关肝细胞癌患者中表达水平及临床意义。方法 选取2017年11月—2020年11月我院收治的HBV相关肝细胞癌患者95例作为肝细胞癌组,另选取同时期HBV相关良性肝病患者100例作为良性组,及健康体检者100例作为对照组。采用实时荧光定量PCR检测外周血血清中miR-338-5p、miR-140-5p表达水平及HBV DNA载量,采用Pearson相关分析分析HBV相关肝细胞癌患者外周血血清中miR-338-5p、miR-140-5p表达水平与HBV DNA载量的关系,采用多因素Logistic回归模型分析影响HBV相关肝细胞癌发生的危险因素;ROC曲线分析miR-338-5p、miR-140-5p、异常凝血酶原-Ⅱ(abnormal prothrombin-Ⅱ,PIVKA-Ⅱ)表达对HBV相关肝细胞癌的诊断价值。结果 外周血血清中miR-338-5p、PIVKA-Ⅱ表达水平从高至低依次为肝细胞癌组[(2.73±0.88)、(103.14,319.19)mAU/ml]、良性组[(1.48±0.40)、(32.70,87.15)mAU/ml]、对照组[(1.00±0.27)、(10.36,16.82)mAU/ml],外周血血清中miR-140-5p表达水平从高至低依次为对照组(1.00±0.25)、良性组(0.72±0.20)、肝细胞癌组(0.38±0.12),两两比较差异均具有统计学意义(P均<0.05);肝细胞癌组患者HBVDNA载量(144.97±47.32)明显高于良性组(75.66±21.91)(P <0.05)。不同TNM分期患者间比较,外周血血清中miR-338-5p、PIVKA-Ⅱ表达水平及HBV DNA载量从高至低依次为TNMⅣ期、Ⅲ期、Ⅱ期、Ⅰ期,外周血血清中miR-140-5p表达水平从高至低依次为TNMⅠ期、Ⅱ期、Ⅲ期、Ⅳ期,两两比较差异均有统计学意义(P均<0.05)。HBV相关肝细胞癌患者外周血血清中miR-338-5p表达水平与HBVDNA载量呈正相关(P <0.05),而miR-140-5p表达水平与HBV DNA载量呈负相关(P <0.05)。HBV相关肝细胞癌发生与患者有无糖尿病史、有无长期饮酒史、HBV DNA载量及外周血血清中miR-338-5p、miR-140-5p、PIVKA-Ⅱ表达水平有关(P均<0.05)。多因素Logistic回归分析显示外�Objective To investigate the expression levels and clinical significance of microRNA-338-5p(miR-338-5p)and microRNA-140-5p(miR-140-5p)in peripheral blood of patients with HBV hepatocellular carcinoma.Methods Ninety-five patients with HBV hepatocellular carcinoma admitted to our hospital from November 2017 to November 2020 were selected as the hepatocellular carcinoma group,another one-hundred patients with HBV related benign liver disease in the same period were selected as the benign group,and 100 healthy people were selected as the control group.The expression levels of miR-338-5p,miR-140-5p and the carrying capacity of HBV DNA in peripheral blood serum were detected by real-time fluorescence quantitative PCR.Pearson test was used to analyze the relationship between the expression levels of miR-338-5p and miR-140-5p in peripheral blood serum of HBV hepatocellular carcinoma patients and HBV DNA carrying capacity,multivariate Logistic regression model was used to analyze the risk factors of HBV hepatocellular carcinoma.ROC curve was used to analyze the diagnostic value of miR-338-5p,miR-140-5p and abnormal prothrombin-Ⅱ(PIVKA-Ⅱ)expression in HBV hepatocellular carcinoma.Results The expression levels of miR-338-5p and PIVKA-Ⅱin peripheral blood serum from high to low was in hepatocellular carcinoma group[(2.73±0.88),(103.14,319.19)mAU/ml],benign group[(1.48±0.40),(32.70,87.15)mAU/ml]and control group[(1.00±0.27),(10.36,6.82)mAU/ml],and the expression level of miR-140-5p in peripheral blood serum from high to low was in control group(1.00±0.25),benign group(0.72±0.20)and hepatocellular carcinoma group(0.38±0.12),the differences were statistically significant(P<0.05);the carrying capacity of HBV DNA in hepatocellular carcinoma group(144.97±47.32)was significantly higher than that in benign group(75.66±21.91)(P<0.05).The expression levels of miR-338-5p,PIVKA-Ⅱ and the carrying capacity of HBV DNA in peripheral blood from high to low were in the order of TNM stage Ⅳ,Ⅲ,Ⅱ and Ⅰ,the expression lev

关 键 词：肝细胞癌 乙型肝炎病毒 微小RNA 微小RNA-338-5p 微小RNA-140-5p 

分 类 号：R735.7[医药卫生—肿瘤]